55 results about "Mumpsvax" patented technology

The invention relates to a composition for killing virus and preventing influenza and a cold prevention plaster prepared by the composition. An aromatic traditional Chinese medicine volatile extract product and fragrant plant essential oil are used as effective components of the plaster; high-molecular colloid, which can be compatible with the effective components and has a stereo network structure, and an excipient are used to wrap the effective components to prepare a microcapsule; the microcapsule is used to coat on a matrix to prepare a tablet; a double faced adhesive tape is used to plaster the tablet at the position close to mouth and nose (such as collar, shoulder, chest and the like) so as to allow the effective components to slowly release at uniform speed. The plaster can be used to kill pathogen and virus in the air and enhance the immunity of upper respiratory tract, has an obvious effect of preventing influenza, and has a certain prevention effect for common cold, hand-foot-mouth disease, varicella, measles, epidemic encephalitis B, epidemic mumps, chronic respiratory tract diseases and the like. The plaster is convenient to use, has fragrant smell and is safe without side-effect.

The present invention provides methods and compositions to induce neutralizing antibodies in mammals to serotypes of dengue virus, measles virus, mumps virus, rubella and/or VZV virus.

The invention relates to a gene chip for detecting important respiratory pathogenic viruses. A preparation method of the gene chip comprises the following steps of: preparing a specific primer; preparing a virus specific probe; preparing an oligonucleotide chip; establishing an RT-PCR (Reverse Transcription-Polymerase Chain Reaction) system; establishing a hybrid system; preparing a visual detection reagent; and establishing a developing method. The gene chip prepared by the invention can be used for simultaneously discriminating nine general respiratory pathogenic viruses comprising A and B type influenza viruses, parainfluenza viruses type 1 and 2, human metapneumovirus, respiratory syncytial virus, measles virus, rubella virus and mumps virus, provides a new solution for quickly detecting the general respiratory pathogenic viruses at high throughout and can provide guidance for monitoring, clinically diagnosing and treating the respiratory pathogenic viruses.

The invention discloses an F-gene type attenuated live mumps vaccine and a preparation method and application thereof, relating to an attenuated live mumps vaccine which is prepared in such a way that a separated F-gene type mumps attenuated live seed is inoculated to the human diploid cells (KMB17 strain) and is subjected to subsequent processes and the freezing-drying technology. The vaccine product has good immunogenicity and safety. The invention provides a cryoprotectant which does not contain glutin, thereby ensuring that the attenuated live mumps vaccine has good appearance, low moisture content and good stability.

The present invention provides a novel vaccine against mumps composed of highly immunogenic rMuVJL2 (recombinant mumps virus Jeryl Lynn2 based). Further, method to develop said immunogenic compositionis described in the present invention. The vaccine according to the present invention is safe, cost effective, highly efficacious and stable and consistent in terms of productivity.

The invention discloses a plaster for curing mumps, relating to a traditional Chinese medicine preparation. The plaster for curing mumps is prepared by processing the following components in parts by weight: 45-55 parts of squama manitis, 250-350 parts of Chinese angelica, 150-300 parts of fossil fragments, 150-250 parts of elephant hide, 100-250 parts of rosin, 15-25 parts of musk, 1500-3000 parts of minium, 50-150 parts of spina gleditsiae, 70-150 parts of sangusis draconis, 50-150 parts of aconitum wardii, 50-150 parts of aconitum kusnenzoffii reichb, 250-350 parts of radix achyranthis bidentatae, 3 long-noded pit vipers, 20 centipedes, 30-60 parts of venenum bufonis, 70-150 parts of coptis, 50-150 parts of nux vomica, 150-300 parts of radix angelicae and 5-6.5 parts of sesame oil. When in use, the plaster is molten, spread on a white cotton cloth and pasted on a wounded part. The plaster can be used for curing mumps at one time without pains and side effect, can become effective immediately, and has the curative effect of 100%.

The invention relates to a recombinant virus and application thereof in mumps virus neutralizing antibody detection, and belongs to the technical field of biology. The invention provides a recombinant virus and a method for detecting a neutralizing antibody of a mumps virus by using the recombinant virus as a neutralizing virus. The recombinant virus takes the mumps virus as a live vector to express a marker gene; the traditional mumps virus neutralizing antibody detection method needs 7 days for final judgment of the result, while the neutralizing antibody detection method disclosed by the invention only needs 3 days, and the result conformity is extremely high; moreover, according to the neutralizing antibody detection method, the neutralizing titer of the antibody in the to-be-detected sample is calculated through fluorescence, the neutralizing antibody detection method can be used in a high-flux fluorescence detection instrument, data can be automatically and electronically stored, and meanwhile, the limitation of human factors in result judgment is shielded.

The invention discloses a mumps virus HN antigen capable of detecting a mumps-resisting virus antibody, especially a mumps-resisting virus neutralized antibody and further discloses application of the antigen in preparation of detection agent for detecting the mumps-resisting virus neutralized antibody and a corresponding detection kit.

The present invention proposes a novel mumps vaccine comprising a homogeneously purified isolate derived from the Jeryl-Lynn strain of mumps virus. The vaccine in the preferred embodiment of the invention produces higher seroconversion rates and antibody titers than known commercial vaccines.

The invention relates to a mumps virus attacking animal model and an establishment method thereof, and belongs to the technical field of biology. The invention provides a mumps virus counteracting animal model. The mumps virus counteracting animal model is an interferon receptor deletion animal which is intravenously injected with mumps virus. Research finds that compared with common mice, the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved after the mumps virus is attacked by the interferon receptor-deleted mice, and compared with intramuscular injection and intranasal injection, the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved after the mumps virus is injected into the interferon receptor-deleted mice through caudal veins, so that the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved. Intravenous injection of the mumps virus to the interferon receptor-deficient animal can break through species limitation, effective infection of the mumps virus in the animal body is realized, and symptoms similar to human infection (for example, remarkable replication in various visceral organs) are formed, so that the mumps virus challenge animal model can be used as the mumps virus challenge animal model.

The invention discloses a concentration and preservation method of mumps attenuated live vaccine viruses. The method comprises the following steps of preparing a cell suspension, preparing monolayer cells, preparing a virus solution, carrying out ultrafiltration concentration, preparing a stock solution, and carrying out cryopreservation to obtain a mumps attenuated live vaccine virus concentratedsolution with extremely low virus titer loss rate, and then a semi-finished product preparation and freeze-drying method is combined, and therefore, it can be guaranteed that the virus titer of the mumps attenuated live vaccine virus vaccine is almost not lost in the long-time storage process.

The invention relates to a recombinant mumps virus particle, a composition and application thereof. The recombinant mumps virus particles have the effects of high efficiency, good preventability and good safety. Therefore, the recombinant mumps virus particles and the composition comprising the same of the present invention can effectively prevent and treat new coronavirus.

The invention discloses agentia for treating mumps. The agentia is prepared through, by weight, 0.6-1.2 parts of rhizoma anemarrhenae, 0.5-1.5 parts of gentians, 0.4-0.8 part of coptis chinensis, 0.2-0.6 part of uroctea, 0.8-1.6 parts of rhizoma dioscoreae nipponicae, 0.5-1.2 parts of manglietia fordiana fruits, 0.8-1.6 parts of catharanthus roseus, 0.5-1.5 parts of Chinese mosla herbs, 0.8-1.2 parts of pinellia ternate, 0.4-0.8 part of cynanchum paniculatum, 0.8-1.2 parts of momordica grosvenori and 0.4-1.0 part of radix angelicae. Traditional Chinese medicine raw materials are compatible in a discriminated mode and supplement each other in function, the effects of relieving exterior syndrome and diffusing wind pathogen, managing qi and activating blood, removing stasis and carrying out detumescence and clearing heat-fire are achieved, the curative effect of treating the mumps is obvious, the function is reliable, and no side effect exists.

The invention relates to application of glucocorticoid in preparation of a medicine for treating and/or preventing respiratory virus infection. The respiratory viruses are selected from SARS-CoV virus, SARS-CoV-2 virus, Middle East respiratory syndrome coronavirus, influenza virus, measles virus, parotitis virus, respiratory syncytial virus, parainfluenza virus, human metapneumovirus, Hendea virus, Nipie virus, rubella virus, rhinovirus, adenovirus, reovirus, coxsackie virus and ECHO virus.

The invention discloses a medicine for treating tuberculosis of cervical lymph nodes, cyclomastopathy and mumps. The medicine is prepared by using the following raw materials by weight part: 4-5 parts of Chinese alangium leaves, 5-8 parts of omoto nipponlily roots, 8-10 parts of rumex madaio, 4-5 parts of Paris rhizomes, 8-10 parts of pokeberry roots, 4-5 parts of radix semiaquilegiae, 8-10 partsof dysosma versipellis and 3-4 parts of toads. A preparation method for the medicine provided by the invention comprises the following steps: weighting all the raw materials by weight part, washing the raw materials and then drying at the temperature below 35 DEG C; milling the raw materials into fine powder and screening by using a 100 mesh sieve; adding 60%-70% alcohol into the powder, wherein the weight of the alcohol is 3-4 times of the total weight of the powder; mixing and soaking for 5-7 days; removing the alcohol; and adding a suitable amount of honey and preparing into paste for externally applying. The medicine provided by the invention has the advantages that only few medicines are externally applied; the pains of a patient caused by taking medicines, injection and surgery are avoided; the application scope is wide; and the medicine is easily absorbed, quickly becomes effective, is high in cure rate, is low in cost and is free from side effect.

The invention provides a disinfectant. The disinfectant comprises the following components: citric acid, lactic acid, malic acid, baicalin alcohol extract, chinaroot greenbrier alcohol extract, bruceajavanica alcohol extract, echinacea purpurea alcohol extract, chloroquine phosphate and water. Through the synergistic effect of citric acid, lactic acid and malic acid, the sterilization and antibacterial effects on bacteria are well achieved, and after baicalin alcohol extract, brucea javanica alcohol extract and echinacea purpurea alcohol extract are compounded, the obvious killing effect on respiratory syncytial viruses and influenza viruses can be well achieved; through the compounding effect of chloroquine phosphate, the inhibition effect on herpes viruses and parotitis viruses is improved, the chinaroot greenbrier alcohol extract plays a good role in inhibiting bacteria, new bacteria and viruses are prevented from growing in the sterilized environment again, and the sterilized environment is kept from being polluted.

The invention provides a system and method for preparing a mumps virus. A mumps virus full-length plasmid having a T7 promoter and auxiliary plasmids are constructed, and the mumps virus is prepared by a reverse genetics method, wherein the four auxiliary plasmids are as follows: a NP plasmid, a P plasmid, an L plasmid and a T7RNAP plasmid, and the T7RNAP plasmid has the sequence of a CMV promoterand the sequence of a DNA for encoding T7 polymerase. The system and method can effectively prepare the mumps virus with higher immunogenicity, and have good application prospects.

The invention discloses a method for subculturing and purifying mumps virus by a dilution method, and belongs to the technical field of attenuated live vaccines. Comprising the following steps: gradually diluting mumps virus mother liquor to 10 <-1 >-10 <-9 > dilution, respectively inoculating obtained virus solutions with 10 <-5 >-10 <-9 > dilution to a cell matrix, culturing at 32-37.0 DEG C, harvesting virus culture supernatant with cell fusion lesion, and detecting virus titer; diluting the harvested viruses step by step again until the dilution degree is 10 <-1 > to 10 <-9 >; culturing at 32-37.0 DEG C, harvesting a virus culture supernatant with obvious cell fusion lesion, and detecting virus titer; and if the virus titer is lower than 6.5 lgCCID50/ml, repeating the operation steps until high-quality virus seeds are obtained. The virus titer of the virus seeds obtained by the method is obviously improved, the stability is good, the gene is not changed, and the effect of improving the quality of attenuated live vaccines is obvious.

The invention provides application of pepper in preparation of a medicine for treating and/or preventing respiratory virus pneumonia. The invention also discloses a method for effectively inhibiting and/or treating coronavirus, human metapneumovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, measles virus, parotitis virus, rubella virus, adenovirus, cytomegalovirus, coxsackie virus, echovirus, herpes simplex virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus, herpes zoster virus and herpes zoster virus. The invention provides a new choice for clinical treatment of infection of respiratory viruses such as chicken pox-herpes zoster virus or rhinovirus.